<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165384</url>
  </required_header>
  <id_info>
    <org_study_id>Preceptis Alpha</org_study_id>
    <nct_id>NCT02165384</nct_id>
  </id_info>
  <brief_title>Hummingbird TTS Ear Tube Delivery Study</brief_title>
  <official_title>Continued Evaluation of the Preceptis Medical, Inc. Tympanostomy Ear Tube Introducer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Preceptis Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Preceptis Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the Hummingbird ear tube delivery system is a
      safe and effective way to put ear tubes in place.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of ears in which the ear tube was successfully delivered across the tympanic membrane</measure>
    <time_frame>intra operative</time_frame>
    <description>Success will be determined at the end of each ear tube procedure, by whether or not the TTS was used to make the incision in the tympanic membrane and to deploy the ear tube. Data may be presented when enrollment has been completed and all pre-operative and procedure data are analyzed. This is estimated to be in the second quarter of 2015.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Otitis Media</condition>
  <arm_group>
    <arm_group_label>Hummingbird TTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ear tube placement with the Hummingbird TTS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ear tube placement with the Hummingbird TTS</intervention_name>
    <description>Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.</description>
    <arm_group_label>Hummingbird TTS</arm_group_label>
    <other_name>Preceptis Medical, Inc. Tympanostomy Tube Introducer System</other_name>
    <other_name>Hummingbird Tympanostomy Tube Delivery System</other_name>
    <other_name>Hummingbird TTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled to undergo tympanostomy tube insertion.

          2. At least 6 months old.

          3. Subject is able and willing to comply with follow-up requirements.

          4. Signed Informed Consent, Parental Consent Form, or Child Assent Form as applicable.

        Exclusion Criteria:

          1. Any condition that in the opinion of the investigator may place the subject at
             greater risk (e.g., pregnancy)

          2. Significantly atrophic tympanic membrane.

          3. Significantly atelectatic tympanic membrane. For example, the tympanic membrane is in
             contact with the promontory of the cochlea.

          4. Anatomy precludes sufficient visualization and access to the tympanic membrane.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Rimell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota and Children's Hospitals and Clinics of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen A Wenell, BA</last_name>
    <email>karen@preceptismedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve Anderson, MS</last_name>
    <email>steve@preceptismedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fairview Maple Grove Surgery Center</name>
      <address>
        <city>Maple Grove</city>
        <state>Minnesota</state>
        <zip>55369</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Majid Shafiei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Sidman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Tibezar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Lander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Rimell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abby Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brianne Roby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frank Rimell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abby Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sam Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chandra Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Beebe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kumar Belani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brianne Roby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shelagh Cofer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Blum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 27, 2015</lastchanged_date>
  <firstreceived_date>June 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tympanostomy</keyword>
  <keyword>myringotomy</keyword>
  <keyword>otitis media</keyword>
  <keyword>ear tubes</keyword>
  <keyword>ear infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
